# Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone

> **NCT00445575** · PHASE2,PHASE3 · COMPLETED · sponsor: **Institut National de la Santé Et de la Recherche Médicale, France** · enrollment: 80 (actual)

## Conditions studied

- Fibrous Dysplasia of Bone

## Interventions

- **DRUG:** risedronate
- **DRUG:** placebo
- **DRUG:** risedronate
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00445575
- **Lead sponsor:** Institut National de la Santé Et de la Recherche Médicale, France
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07-22
- **Primary completion:** 2017-12
- **Final completion:** 2017-12-07
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2021-08-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00445575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00445575, "Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00445575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*